AKT2 Antibody (11F6.B2)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-44216

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-44216
NBP2-44216-0.05mg
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Applications

ELISA, Flow Cytometry, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2a Kappa Clone # 11F6.B2

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all Akt2 Antibodies »

Product Summary for AKT2 Antibody (11F6.B2)

Immunogen

AKT2 Antibody (11F6.B2) was produced by repeated immunizations with a synthetic peptide corresponding to internal residues of human AKT2 protein. (Uniprot: P31751)

Reactivity Notes

Cross reactivity with AKT2 from other species has not been determined, however, the sequence of the immunogen shows 88% identity to mouse and 90% identity with rat, therefore, cross reactivity is expected

Specificity

Anti-AKT2 antibody is directed against human AKT2. The antibody detects both unphosphorylated and phosphorylated forms of the protein.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2a Kappa

Description

This antibody was purified from concentrated tissue culture supernate by Protein G chromatography

Store vial at -20C prior to opening. Aliquot contents and freeze at -20C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4C as an undiluted liquid. Dilute only prior to immediate use.

Scientific Data Images for AKT2 Antibody (11F6.B2)

Western Blot: AKT2 Antibody (11F6.B2) [NBP2-44216]

Western Blot: AKT2 Antibody (11F6.B2) [NBP2-44216]

Western Blot: AKT2 Antibody (11F6.B2) [NBP2-44216] - lane 1: LnCap lysate Lane 2: Jurkat lysate. Lane 3: MDA-MB 468 lysate. Load: 5 Ug per lane.
Western Blot: AKT2 Antibody (11F6.B2) [NBP2-44216]

Western Blot: AKT2 Antibody (11F6.B2) [NBP2-44216]

Western Blot: AKT2 Antibody (11F6.B2) [NBP2-44216] - lane 1: GST-AKT1. Lane 2: GST-AKT2. Lane 3: GST-AKT3. Load: 50 ng per lane.
ELISA: AKT2 Antibody (11F6.B2) [NBP2-44216]

ELISA: AKT2 Antibody (11F6.B2) [NBP2-44216]

ELISA: AKT2 Antibody (11F6.B2) [NBP2-44216] - ELISA of Rat Monoclonal anti-AKT2 Antigen: GST AKT1, GST AKT2, GST AKT3. Coating amount: starting from 50 ng/well.
View 1 more images

Applications for AKT2 Antibody (11F6.B2)

Application
Recommended Usage

ELISA

1:2000-1:10000

Flow Cytometry

1:10-1:1000

Immunohistochemistry

20 ug/ml

Western Blot

1:500-1:2000
Application Notes
This product is tested for ELISA and western blotting. This antibody is suitable for immunohistochemistry. Expect a band approximately 56 kDa in size corresponding to AKT2 protein by western blotting in the appropriate cell lysate or extract. This monoclonal antibody reacts with human AKT. Specific conditions for reactivity should be optimized by the end user. For immunohistochemistry we recommend the use of fresh frozen tissues. Attempts at staining paraffin-embedded formalin fixed tissues were negative. No pre-treatment of sample is required.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative

0.01% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles.

Background: Akt2

AKT (also known as protein kinase B (PKB) and RAC (related to A and C kinases)) is a critical intracellular serine/threonine kinase that translates signals from extracellular stimuli including growth factors, cytokines and neurotransmitters (1). AKT signaling plays critical roles in cell growth, proliferation, survival and differentiation (1). It is also involved in organogenesis, angiogenesis and metabolism. Three mammalian AKT isoforms have been identified. The AKT pathway can be activated by any of the three members who share a high level of protein homology but are independently encoded by AKT1 (PKB alpha; 14q32.32), AKT2 (PKB beta; 19q13.2), or AKT3 (PKB gamma; 1q44) (1, 2). Each AKT family member contains an N-terminal pleckstrin homology (PH) domain, a central kinase domain, and a C-terminal regulatory domain. AKT mediates many of the downstream events of phosphatidylinositol 3-kinase (PI3-K), a lipid kinase activated by growth factors, cytokines and insulin. PI3-K recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. AKT has two main phosphorylation sites (Ser473 and Thr308, predicted molecular weight 56 kDa) (3, 4). Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus including mammalian target of rapamycin (mTOR).

The main function of AKT is to control inhibition of apoptosis and promote cell proliferation. Survival factors can activate AKT Ser473 and Thr308 phosphorylation sites in a transcription-independent manner, resulting in the inactivation of apoptotic signaling transduction through the tumor suppressor PTEN, an antagonist to PI3-K (5). PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP3) phosphatase, opposing PI3K activity by decreasing availability of PIP3 to proliferating cells, leading to overexpression and inappropriate activation of AKT noted in many types of cancer.

AKT1 function has been linked to overall physiological growth and function (2). AKT1 has been correlated with proteus syndrome, a rare disorder characterized by overgrowth of various tissues caused by a mosaic variant in the AKT1 gene in humans.

AKT2 is strongly correlated with Type II diabetes, including phenotypes of insulin resistance, hyperglycemia and atherosclerosis (2, 6).

The function of AKT3 is specifically associated to brain development, where disruptions to AKT3 are correlated with microcephaly, hemimegalencephaly, megalencephaly and intellectual disabilities (2).

References

1. Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015). The PI3K/AKT/mTOR interactive pathway. Mol Biosyst, 11(7), 1946-1954. doi:10.1039/c5mb00101c

2. Cohen, M. M., Jr. (2013). The AKT genes and their roles in various disorders. Am J Med Genet A, 161a(12), 2931-2937. doi:10.1002/ajmg.a.36101

3. Georgescu, M. M. (2010). PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer, 1(12), 1170-1177. doi:10.1177/1947601911407325

4. Mishra, P., Paital, B., Jena, S., Swain, S. S., Kumar, S., Yadav, M. K., . . . Samanta, L. (2019). Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFkB/AKT/mTOR/KEAP1 signalling in rat heart. Sci Rep, 9(1), 7408. doi:10.1038/s41598-019-43320-5

5. Wedel, S., Hudak, L., Seibel, J. M., Juengel, E., Oppermann, E., Haferkamp, A., & Blaheta, R. A. (2011). Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate, 71(7), 722-735. doi:10.1002/pros.21288

6. Rotllan, N., Chamorro-Jorganes, A., Araldi, E., Wanschel, A. C., Aryal, B., Aranda, J. F., . . . Fernandez-Hernando, C. (2015). Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis. Faseb j, 29(2), 597-610. doi:10.1096/fj.14-262097

Long Name

v-Akt Murine Thymoma Viral Oncogene Homolog 2

Alternate Names

PKB beta, RAC-beta

Gene Symbol

AKT2

UniProt

P31751

Additional Akt2 Products

Product Documents for AKT2 Antibody (11F6.B2)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for AKT2 Antibody (11F6.B2)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.